Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247797 | 0.79 | CARM1 (0.56) | L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL7248998 | 0.78 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1NPC1CYP3A4CYP2D6 | |
| SCHEMBL7822101 | 0.77 | L3MBTL1 (0.60) | L3MBTL1ALDH1A1NPC1CYP3A4CYP2D6 | |
| SCHEMBL7248629 | 0.76 | L3MBTL1 (0.62) | L3MBTL1OPRM1KCNH2HRH3 | |
| SCHEMBL2603281 | 0.76 | CARM1 (0.55) | CYP3A4CYP2D6KCNH2HRH3TSHR | |
| SCHEMBL1863189 | 0.74 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL6005396 | 0.73 | L3MBTL1 (0.62) | L3MBTL1OPRM1KDM4EKCNH2 | |
| SCHEMBL1857503 | 0.73 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1HSD17B10TSHRRAB9A | |
| SCHEMBL2606080 | 0.72 | OPRM1 (0.51) | OPRM1CYP3A4CYP2D6KCNH2TSHR | |
| SCHEMBL4577442 | 0.72 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1OPRM1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | L3MBTL1 1288/4885ALDH1A1 2672/4885OPRM1 4/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | L3MBTL1 1288/4885ALDH1A1 2672/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.